|
| Press Releases |
|
 |
|
| Monday, December 9, 2024 |
|
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
| China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
| Monday, December 2, 2024 |
|
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
| China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
| Monday, October 21, 2024 |
|
|
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area |
| China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. more info >> |
|
| Tuesday, September 24, 2024 |
|
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
| Friday, August 16, 2024 |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
| Monday, August 5, 2024 |
|
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
| Tuesday, July 16, 2024 |
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
| In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
| Tuesday, June 25, 2024 |
|
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
| On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
| Tuesday, June 18, 2024 |
|
|
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China |
| more info >> |
|
| Tuesday, April 23, 2024 |
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets ("Desidustat Tablets" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
FILMART and EntertainmentPulse draw about 8,000 industry participants
Mar 20, 2026 20:40 HKT/SGT
|
|
|
TANAKA Announces Executive Appointments
Mar 20, 2026 20:00 HKT/SGT
|
|
|
MarketingPulse and eTailingPulse attract more than 1,700 industry professionals
Mar 20, 2026 11:42 HKT/SGT
|
|
|
Anticipation of Unitree Robotics' IPO Heats Up, Value Revaluation for Shoucheng Holdings (0697.HK) Expected
Mar 20, 2026 08:30 HKT/SGT
|
|
|
Global Capital Reset Takes Centre Stage at Hall Chadwick's U.S. Capital Access Forum in Singapore
Mar 20, 2026 07:00 HKT/SGT
|
|
|
U.S. Polo Assn. Unveils 2026 Spring-Summer Global Collection, Inspired by Coastal Charleston, South Carolina
Mar 19, 2026 19:00 HKT/SGT
|
|
|
Honda to Expand Motorcycle Production Capacity in India by Adding New Motorcycle Production Line to its Second Plant
Mar 19, 2026 18:32 JST
|
|
|
Honda WN7 Electric Motorcycle Wins Gold Award at iF DESIGN AWARD 2026
Mar 19, 2026 18:16 JST
|
|
|
Hitachi, The University of Technology Sydney and NTT DATA Sign MoU to Accelerate Green Transformation in Australia
Mar 19, 2026 18:08 JST
|
|
|
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of Care.com from IAC
Mar 19, 2026 15:15 HKT/SGT
|
|
|
MHI Thermal Systems Expands Lineup of Air-to-Water Heat Pumps for the European Market
Mar 19, 2026 15:14 JST
|
|
|
DENSO Invests in Next Core Technologies to Enhance Performance of Electric Vehicles
Mar 19, 2026 14:25 JST
|
|
|
NEC Completes Design of Equipment for Technology Demonstration Satellite Aimed at Creating Japan's First Optical Communication Satellite Constellation
Mar 19, 2026 11:05 JST
|
|
|
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Mar 19, 2026 10:54 JST
|
|
|
Hitachi is recognized as one of the World's Most Ethical Companies(R) for a second consecutive year
Mar 19, 2026 10:41 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
